Streetbeat News

Price Targets

AGIO

Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Agios Pharmaceuticals (NASDAQ:AGIO) and lowers the price target from $32 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:18 pm

CHUY

Wedbush analyst Nick Setyan has maintained an 'Outperform' rating on Chuy's Holdings (NASDAQ:CHUY) but lowered the price target from $42 to $41.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:18 pm

PZZA

Wedbush analyst Nick Setyan has maintained an 'Outperform' rating on Papa John's International (NASDAQ:PZZA), but lowered the price target from $95 to $73.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:14 pm

ZG

Susquehanna analyst Shyam Patil maintains a Neutral rating on Zillow Gr (NASDAQ:ZG) and lowers the price target from $50 to $36.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:13 pm

CVCO

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Cavco Indus (NASDAQ:CVCO) and maintained a $390 price target.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:13 pm

SWKS

Susquehanna analyst Christopher Rolland has maintained a positive outlook on Skyworks Solutions (NASDAQ:SWKS), but has lowered the price target from $115 to $110.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:12 pm

MRO

Susquehanna analyst Biju Perincheril maintains a positive outlook on Marathon Oil (NYSE:MRO) and has raised the price target from $34 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:11 pm

MCHP

Susquehanna analyst Christopher Rolland has maintained a positive rating on Microchip Technology (NASDAQ:MCHP) but lowered the price target from $95 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:10 pm

DKNG

Susquehanna analyst Joseph Stauff maintains a positive outlook on DraftKings (NASDAQ:DKNG), but has lowered the price target from $40 to $37.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:08 pm

KURA

Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating on Kura Oncology (NASDAQ:KURA) but lowered the price target from $40 to $37.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:06 pm